Acute and Chronic Management of Atrial Fibrillation in Patients With Late-Stage CKD

American Journal of Kidney Diseases

Volumn 53, Issue 4, 2009, Pages 701-710

  Aronow, Wilbert S ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

anticoagulants; atrial fibrillation; Chronic kidney disease

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC GLYCOSIDE; CARVEDILOL; DIGOXIN; DILTIAZEM; ESMOLOL; METOPROLOL; MEVINOLIN; PROPRANOLOL; SIMVASTATIN; SOTALOL; VERAPAMIL; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; ATRIOVENTRICULAR BLOCK; BLEEDING; BLOOD PRESSURE; CARDIOVASCULAR RISK; CARDIOVERSION; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SELECTIVITY; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; LOADING DRUG DOSE; LUNG TOXICITY; MORTALITY; PROGNOSIS; RISK FACTOR; SINUS RHYTHM; STROKE; THROMBOEMBOLISM; THYROID TOXICITY; UNSPECIFIED SIDE EFFECT;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CHRONIC DISEASE; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; ELECTRIC COUNTERSHOCK; FEMALE; HEART RATE; HUMANS; KIDNEY DISEASES; RISK FACTORS; STROKE; STROKE VOLUME; WARFARIN;

EID: 62749130592     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2009.01.257     Document Type: Article

References (80)

1. Wolf P.A., Abbott R.D., and Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22 (1991) 983-988
2. Aronow W.S., Ahn C., and Gutstein H. Prevalence of atrial fibrillation and association of atrial fibrillation with prior and new thromboembolic stroke in older patients. J Am Geriatr Soc 44 (1996) 521-523
3. Aronow W.S., Ahn C., and Gutstein H. Prevalence and incidence of cardiovascular disease in 1,160 older men and 2,464 older women in a long-term health care facility. J Gerontol A Biol Sci Med Sci 57 (2002) M45-M46
4. Furberg C.D., Psaty B.M., Manolio T.A., Gardin J.M., Smith V.E., and Rautaharju P.M. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 74 (1994) 236-241
5. Mendelson G., and Aronow W.S. Underutilization of warfarin in older persons with chronic nonvalvular atrial fibrillation at high risk for developing stroke. J Am Geriatr Soc 46 (1998) 1423-1424
6. Psaty B.M., Manolio T.A., Kuller L.H., et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 96 (1997) 2455-2461
7. Danias P.G., Caulfield T.A., Weigner M.J., Silverman D.I., and Manning W.J. Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm. J Am Coll Cardiol 31 (1998) 588-592
8. Abe S., Yoshizawa M., Nakanishi N., et al. Electrocardiographic abnormalities in patients receiving hemodialysis. Am Heart J 131 (1996) 1137-1144
9. Fabbian F., Catalano C., Lambertini D., et al. Clinical characteristics associated to atrial fibrillation in chronic hemodialysis patients. Clin Nephrol 54 (2000) 234-239
10. Vazquez E., Sanchez-Perales C., Borrego F., et al. Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J 140 (2000) 886-890
11. Genovesi S., Pogliani D., Faini A., et al. Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis 46 (2005) 897-902
12. Das M., Aronow W.S., McClung J.A., and Belkin R.N. Increased prevalence of coronary artery disease, silent myocardial ischemia, complex ventricular arrhythmias, atrial fibrillation, left ventricular hypertrophy, mitral annular calcium, and aortic valve calcium in patients with chronic renal insufficiency. Cardiol Rev 14 (2006) 14-17
13. Atar I., Konas D., Acikel S., et al. Frequency of atrial fibrillation and factors related to its development in dialysis patients. Int J Cardiol 106 (2006) 47-51
14. Abbott K.C., Trespalacios F.C., Taylor A.J., and Agodoa L.Y. Atrial fibrillation in chronic dialysis patients in the United States: risk factors for hospitalization and mortality. BMC Nephrol 4 (2003) 1
15. Kannel W.B., Abbott R.D., Savage D.D., and McNamara P.M. Epidemiologic features of chronic atrial fibrillation: The Framingham Study. N Engl J Med 306 (1982) 1018-1022
16. Benjamin E.J., Wolf P.A., D'Agostino R.B., Silbershatz H., Kannel W.B., and Levy D. Impact of atrial fibrillation on the risk of death. The Framingham Heart Study. Circulation 98 (1998) 946-952
17. Aronow W.S., Ahn C., Mercando A.D., and Epstein S. Correlation of atrial fibrillation, paroxysmal supraventricular tachycardia, and sinus rhythm with incidences of new coronary events in 1,359 patients, mean age 81 years, with heart disease. Am J Cardiol 75 (1995) 182-184
18. Friberg J., Scharling H., Gadsboll N., et al. Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (the Copenhagen City Heart Study). Am J Cardiol 94 (2004) 889-894
19. Dagres N., Nieuwlaat R., Vardas P.E., et al. Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe. A report from the Euro Heart Survey on Atrial Fibrillation. J Am Coll Cardiol 49 (2007) 572-577
20. Aronow W.S., Ahn C., Mercando A.D., Epstein S., and Gutstein H. Correlation of paroxysmal supraventricular tachycardia, atrial fibrillation, and sinus rhythm with incidences of new thromboembolic stroke in 1,476 old-old patients. Aging Clin Exp Res 8 (1996) 32-34
21. Gage B.F., Waterman A.D., Shannon W., et al. Validation of clinical classification schemes for predicting stroke. Results from the national registry of atrial fibrillation. JAMA 285 (2001) 2864-2870
22. Khumri T.M., Idupulapati M., Rader V.J., Nayyar S., Stoner C.N., and Main M.L. Clinical and echocardiographic markers of mortality risk in patients with atrial fibrillation. Am J Cardiol 99 (2007) 1733-1736
23. Herzog C.A., Ma J.Z., and Collins A.J. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 339 (1998) 799-805
24. D'Elia J.A., Weinrauch L.A., Gleason R.E., et al. Application of the ambulatory 24-hour electrocardiogram in the prediction of cardiac death in dialysis patients. Arch Intern Med 148 (1988) 2381-2385
25. Jungers P., Massy Z.A., Khoa T.N., et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrol Dial Transplant 12 (1997) 2597-2602
26. Parfrey P.S., and Foley R.N. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 10 (1999) 1608-1615
27. Aronow W.S., Ahn C., Mercando A.D., and Epstein S. Prevalence of coronary artery disease, complex ventricular arrhythmias, and silent myocardial ischemia and incidence of new coronary events in older persons with chronic renal insufficiency and with normal renal function. Am J Cardiol 86 (2000) 1142-1143
28. Genovesi S., Vincenti A., Rossi E., et al. Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis 51 (2008) 255-262
29. Vazquez E., Sanchez-Perales C., Lozano C., et al. Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis. Am J Cardiol 92 (2003) 868-871
30. Vazquez-Ruiz de Castroviejoa E., Sanchez-Perales C., Lozano-Cabezas C., et al. Incidence of atrial fibrillation in hemodialysis patients. A prospective long-term follow-up study. Rev Esp Cardiol 59 (2006) 779-784
31. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 323 (1990) 1505-1511
32. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154 (1994) 1449-1457
33. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 348 (1996) 633-638
34. European Atrial Fibrillation Trial (EAFT) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342 (1993) 1255-1262
35. Peterson P., Boysen G., Godtfredsen J., Andersen E.D., and Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. Lancet 1 (1989) 175-179
36. Stroke Prevention in Atrial Fibrillation Investigators. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. N Engl J Med 322 (1990) 863-868
37. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: Final results. Circulation 84 (1991) 527-539
38. Connolly S.J., Laupacis A., Gent M., et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 18 (1991) 345-355
39. Ezekowitz M.D., Bridgers S.L., James K.E., et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 327 (1992) 1406-1412
40. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 343 (1994) 687-691
41. Gullov A.L., Koefoed B.G., Petersen P., et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation. Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 158 (1998) 1513-1521
42. Aronow W.S., Ahn C., Kronzon I., and Gutstein H. Incidence of new thromboembolic stroke in persons ≥62 years old with chronic atrial fibrillation treated with warfarin versus aspirin. J Am Geriatr Soc 47 (1999) 366-368
43. Aronow W.S., Ahn C., Kronzon I., and Gutstein H. Effect of warfarin versus aspirin on the incidence of new thromboembolic stroke in older persons with chronic atrial fibrillation and abnormal and normal left ventricular ejection fraction. Am J Cardiol 85 (2000) 1033-1035
44. Fang M.C., Singer D.E., Chang Y., et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation. The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Circulation 112 (2005) 1687-1691
45. Ruiz-Nodar J.M., Marin F., Hurtado J.A., et al. Anticoagulant therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation. J Am Coll Cardiol 51 (2008) 818-825
46. Korantzopoulos P., Kokkoris S., Liu T., Protopsaltis I., Li G., and Goudevenos J.A. Atrial fibrillation in end-stage renal disease. Pacing Clin Electrophysiol 30 (2007) 1391-1397
47. Fuster V., Ryden L.E., Asinger R.W., et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary. Am Coll Cardiol 38 (2001) 1231-1265
48. Vazquez E., Sanchez-Perales C., Garcia-Cortes J., et al. Ought dialysis patients with atrial fibrillation be treated with oral anticoagulants?. Int J Cardiol 87 (2003) 135-139
49. Wright J.R., and Kalra P.A. Ought dialysis patients with atrial fibrillation be treated with oral anticoagulants?. Int J Cardiol 87 (2003) 139-141
50. Elliott M.J., Zimmerman D., and Holden R.M. Warfarin anticoagulation in hemodialysis patients: A systematic review of bleeding rates. Am J Kidney Dis 50 (2007) 433-440
51. Tveit D.P., Hypolite I.O., Hshieh P., et al. Chronic dialysis patients have high risk for pulmonary embolism. Am J Kidney Dis 39 (2002) 1011-1017
52. Nishimura M., Hashimoto T., Kobayashi H., et al. The high incidence of left atrial appendage thrombosis in patients on maintenance haemodialysis. Nephrol Dial Transplant 18 (2003) 2339-2347
53. Quinn R.R., Naimark D.M.J., Oliver M.J., et al. Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation?. A cost-utility analysis. Am J Kidney Dis 50 (2007) 421-432
54. Abbott K.C., Neff R.T., Bohen E.M., and Narayan R. Anticoagulation for chronic atrial fibrillation in hemodialysis patients: which fruit from the decision tree?. Am J Kidney Dis 50 (2007) 345-348
55. Aronow W.S., and Sorbera C. Supraventricular tachyarrhythmias in the elderly. In: Aronow W.S., Fleg J.L., and Rich M.W. (Eds). Cardiovascular Disease in the Elderly. (ed 4) (2008), Informa Healthcare, New York, NY 577-603
56. Aronow W.S. Might losartan reduce sudden cardiac death in diabetics with hypertension?. Lancet 362 (2003) 591-592
57. K/DOQI Workgroup. Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. Am J Kidney Dis 45 suppl 3 (2005) S1-S153
58. Frishman W.H., Aronow W.S., and Cheng-Lai A. Cardiovascular drug therapy in the elderly. In: Aronow W.S., Fleg J.L., and Rich M.W. (Eds). Cardiovascular Disease in the Elderly. (ed 4) (2008), Informa Healthcare, New York, NY 99-135
59. Agarwal R. Supervised atenolol therapy in the management of hemodialysis hypertension. Kidney Int 55 (1999) 1528-1535
60. Letavernier E., Couzi L., Delmas Y., et al. Verapamil and mild hyperkalemia in hemodialysis patients: a potentially hazardous association. Hemodial Int 10 (2006) 170-172
61. Falk R.H., and Leavitt J.I. Digoxin for atrial fibrillation: a drug whose time has gone?. Ann Intern Med 114 (1991) 573-575
62. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 319 (1988) 385-392
63. Goldstein R.E., Boccuzzi S.J., Cruess D., et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 83 (1991) 52-60
64. Gold R.L., Haffajee C.I., Charos G., et al. Amiodarone for refractory atrial fibrillation. Am J Cardiol 57 (1986) 124-127
65. Greene H.L., and CASCADE Investigators. The CASCADE study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. Am J Cardiol 72 (1993) 70F-74F
66. Herre J., Sauve M., Malone P., Griffin J.C., Helmy I., and Langberg J.J. Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol 13 (1989) 442-449
67. Freudenberger R.S., Wilson A.C., Kostis J.B., and AFFIRM Investigators and Committees. Comparison of rate versus rhythm control for atrial fibrillation in patients with left ventricular dysfunction (from the AFFIRM study). Am J Cardiol 100 (2007) 247-252
68. Van Gelder I.C., Hagens V.E., Bosker H.A., et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347 (2002) 1834-1840
69. Rienstra M., Van Veldhuisen D.J., Hagens V.E., et al. Gender-related differences in rhythm control treatment in persistent atrial fibrillation. Data of the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol 46 (2005) 1298-1306
70. Al-Khatib S.M., Shaw L.K., Lee K.L., et al. Is rhythm control superior to rate control in patients with atrial fibrillation and congestive heart failure?. Am J Cardiol 94 (2004) 797-800
71. Roy D., Talajic M., Nattel S., et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358 (2008) 2667-2677
72. The Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347 (2002) 1825-1833
73. Hunt S.A., Abraham W.T., Feldman A.M., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult-summary article. J Am Coll Cardiol 46 (2005) 1116-1143
74. Aronow W.S. Treatment of heart failure with abnormal left ventricular systolic function in the elderly. Heart Fail Clin 3 (2008) 423-436
75. Ozcan C., Jahangir A., Friedman P.A., et al. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med 344 (2001) 1043-1051
76. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 39 suppl 1 (2002) S1-S246
77. Grundy S.M., Cleeman J.I., Merz C.N.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
78. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 (2006) 549-559
79. Sukhija R., Burac Z., Kakar P., et al. Effect of statins on the development of renal dysfunction. Am J Cardiol 101 (2008) 975-979
80. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Eng J Med 353 (2005) 238-248